Androgen Receptor Signaling Inhibitors in Nonmetastatic Castration-resistant Prostate Cancer and Risk of Cardiovascular Toxicity: All That Glitters Isn't Gold.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 32800724.
- Also identified by DOI 10.1016/j.eururo.2020.07.036.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Androgen receptor signaling inhibitors have a metastasis-free survival benefit for men with nonmetastatic castration-resistant prostate cancer. The latest updates for the PROSPER, SPARTAN, and ARAMIS trials also demonstrate an overall survival benefit. However, the cardiovascular toxicity associated with prolonged use of these agents should be taken into consideration before initiating therapy.
Medical subject headings
- Androgen Receptor Antagonists
- Cardiovascular Diseases
- Heart Disease Risk Factors
- Prostatic Neoplasms, Castration-Resistant